NCT00697866View on ClinicalTrials.gov

Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control

PHASE3CompletedINTERVENTIONAL
Enrollment

951

Participants

Timeline

Start Date

August 31, 2000

Primary Completion Date

February 28, 2001

Conditions
Hepatitis B
Interventions
BIOLOGICAL

HBV-MPL vaccine 208129

3 consecutive lots; 3-dose intramuscular injection

BIOLOGICAL

Engerix™-B

3-dose intramuscular injection

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00697866 - Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control | Biotech Hunter | Biotech Hunter